Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAdVEC and HER2-Specific CAR T Cells in Advanced HER2 Positive Solid Tumors
NCT03740256Phase 1Recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Dec 2020
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in solid tumor, sponsored by Baylor College of Medicine. Primary endpoint: Dose Limiting Toxicity at 4 weeks. Started Dec 2020; status: recruiting.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03740256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03740256.